Literature DB >> 17392817

c-Maf nuclear oncoprotein is frequently expressed in multiple myeloma.

Hong Chang, Q Qi, W Xu, B Patterson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17392817     DOI： 10.1038/sj.leu.2404669

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  9 in total

1.  Regulation of c-Maf and αA-Crystallin in Ocular Lens by Fibroblast Growth Factor Signaling.

Authors:  Qing Xie; Rebecca McGreal; Raven Harris; Chun Y Gao; Wei Liu; Lixing W Reneker; Linda S Musil; Ales Cvekl
Journal:  J Biol Chem       Date:  2015-12-30       Impact factor: 5.157

2.  MAF protein mediates innate resistance to proteasome inhibition therapy in multiple myeloma.

Authors:  Ya-Wei Qiang; Shiqiao Ye; Yu Chen; Amy F Buros; Ricky Edmonson; Frits van Rhee; Bart Barlogie; Joshua Epstein; Gareth J Morgan; Faith E Davies
Journal:  Blood       Date:  2016-10-28       Impact factor: 22.113

3.  The transmembrane protein TMEPAI induces myeloma cell apoptosis by promoting degradation of the c-Maf transcription factor.

Authors:  Yanyun Du; Yan Liu; Yujia Xu; Jiaxiang Juan; Zubin Zhang; Zhuan Xu; Biyin Cao; Qi Wang; Yuanying Zeng; Xinliang Mao
Journal:  J Biol Chem       Date:  2018-02-21       Impact factor: 5.157

Review 4.  MafA and MafB activity in pancreatic β cells.

Authors:  Yan Hang; Roland Stein
Journal:  Trends Endocrinol Metab       Date:  2011-06-28       Impact factor: 12.015

5.  Small molecule inhibition of cytoskeletal dynamics in melanoma tumors results in altered transcriptional expression patterns of key genes involved in tumor initiation and progression.

Authors:  Carrie Spencer; John Montalvo; Sarah R McLaughlin; Brad A Bryan
Journal:  Cancer Genomics Proteomics       Date:  2011 Mar-Apr       Impact factor: 4.069

6.  t(14;16)-positive multiple myeloma shows negativity for CD56 expression and unfavorable outcome even in the era of novel drugs.

Authors:  T Narita; A Inagaki; T Kobayashi; Y Kuroda; T Fukushima; M Nezu; S Fuchida; H Sakai; N Sekiguchi; I Sugiura; Y Maeda; H Takamatsu; N Tsukamoto; D Maruyama; Y Kubota; M Kojima; K Sunami; T Ono; M Ri; K Tobinai; S Iida
Journal:  Blood Cancer J       Date:  2015-02-27       Impact factor: 11.037

7.  DEPTOR maintains plasma cell differentiation and favorably affects prognosis in multiple myeloma.

Authors:  Dalia Quwaider; Luis A Corchete; Irena Misiewicz-Krzeminska; María E Sarasquete; José J Pérez; Patryk Krzeminski; Noemí Puig; María Victoria Mateos; Ramón García-Sanz; Ana B Herrero; Norma C Gutiérrez
Journal:  J Hematol Oncol       Date:  2017-04-18       Impact factor: 17.388

8.  Immunohistochemistry for identification of CCND1, NSD2, and MAF gene rearrangements in plasma cell myeloma.

Authors:  Takayuki Murase; Masaki Ri; Tomoko Narita; Keiichiro Fujii; Ayako Masaki; Shinsuke Iida; Hiroshi Inagaki
Journal:  Cancer Sci       Date:  2019-07-11       Impact factor: 6.716

9.  Clinical implications of c-maf expression in plasma cells from patients with multiple myeloma.

Authors:  GuoQing Wei; LiJun Wang; HanJin Yang; XiaoYan Han; GaoFeng Zheng; WeiYan Zheng; Jie Sun; JiMin Shi; WenJun Wu; Yi Zhao; DongHua He; Bo Wang; Zhen Cai; JingSong He
Journal:  Exp Hematol Oncol       Date:  2017-05-26
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.